Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Bavituximab by Feng Biosciences for Gliosarcoma: Likelihood of Approval
Bavituximab is under clinical development by Feng Biosciences and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II...
Data Insights
Bavituximab by Feng Biosciences for Glioblastoma Multiforme (GBM): Likelihood of Approval
Bavituximab is under clinical development by Feng Biosciences and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...